US2013023562A1PendingUtilityA1

Novel piperidine derivatives

Assignee: ASTRAZENECA ABPriority: Jul 21, 2005Filed: Jul 27, 2012Published: Jan 24, 2013
Est. expiryJul 21, 2025(expired)· nominal 20-yr term from priority
A61P 7/02A61P 37/00A61P 37/08A61P 9/00A61P 9/10A61P 37/06A61P 31/04A61P 35/00A61P 31/12A61P 27/16A61P 29/00A61P 31/00A61P 25/28A61P 27/02A61P 31/18A61P 17/06A61P 13/10A61P 15/10A61P 15/00A61P 11/06A61P 19/00A61P 1/04A61P 1/16A61P 19/08A61P 19/02A61P 19/10C07D 211/46A61P 17/14A61P 19/06A61P 11/08A61P 13/02A61P 11/00C07C 309/73A61P 13/12A61P 1/00A61P 17/00A61P 17/10C07D 401/06
44
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) mediated disease state.

Claims

exact text as granted — not AI-modified
1 . The compound (S)-{4-[4-(3,4-dichloro-2-methyl-phenoxy)-piperidin-1-ylmethyl]-piperidin-1-yl}-3-(4-fluoro-phenyl)-propionic acid, or a pharmaceutically acceptable salt thereof. 
     
     
         2 . A pharmaceutically acceptable salt of (S)-{4-[4-(3,4-dichloro-2-methyl-phenoxy)-piperidin-1-ylmethyl]-piperidin-1-yl}-3-(4-fluoro-phenyl)-propionic acid which is a sodium, potassium or (CH 2 CH 2 OH) 3 NH +  salt, or a hydrochloride, dihydrochloride, hydrobromide, phosphate, sulfate, acetate, fumarate, maleate, malonate, succinate, tartrate, citrate, oxalate, methanesulfonate, benzenesulfonate or p-toluenesulfonic acid salt. 
     
     
         3 . The compound (S)-{4-[4-(3,4-dichloro-2-methyl-phenoxy)-piperidin-1-ylmethyl]-piperidin-1-yl}-3-(4-fluoro-phenyl)-propionic acid. 
     
     
         4 . A polymorph of (S)-{4-[4-(3,4-dichloro-2-methyl-phenoxy)-piperidin-1-ylmethyl]-piperidin-1-yl}-3-(4-fluoro-phenyl)-propionic acid (Form I) having an X-ray powder diffraction pattern containing specific peaks at: 2.2 (±0.1°), 2.7 (±0.1°), 7.1 (±0.1°), 10.7 (±0.1°), 13.3 (±0.1°) and 18.8 (±0.1°) 2θ. 
     
     
         5 . A polymorph of (S)-{4-[4-(3,4-dichloro-2-methyl-phenoxy)-piperidin-1-ylmethyl]-piperidin-1-yl}-3-(4-fluoro-phenyl)-propionic acid (Form II) having an X-ray powder diffraction pattern containing specific peaks at: 2.2 (±0.1°), 2.67 (±0.1°), 7.2 (±0.1°), 13.2 (±0.1°), 17.0 (±0.1°), 17.4 (±0.1°), 19.1 (±0.1°), 19.4 (±0.1°), 21.1 (±0.1°), 24.4 (±0.1°) and 25.2 (±0.1°) 2θ. 
     
     
         6 . A pharmaceutical composition which comprises a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in  claim 1 , or a salt as claimed in  claim 2 , and a pharmaceutically acceptable adjuvant, diluent or carrier.

Join the waitlist — get patent alerts

Track US2013023562A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.